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AbstrAct
Current larynx preservation treatments have achieved an improvement of 
laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities 
and recurrences. At present, there is no evidence to select the group of patients that 
may benefit from preservation approaches instead of surgery. Therefore, laryngeal 
biomarkers could facilitate pretreatment identification of patients who could respond 
to chemoradiation-based therapy. In this study, we evaluated retrospectively 53 
patients with larynx cancer to determine whether gH2AX phosphorylation (pH2AX) 
alone or in combination with the membrane protein MAP17 (PDZK1IP1) could be used 
as prognostic biomarkers. We also evaluated whether the completion of cisplatin 
treatment and radiotherapy could predict survival in combination with pH2AX. 
We found that the dose of cisplatin received but not the length of the radiotherapy 
influenced LDS. High-pH2AX expression was associated with prolonged LDS (HR 0.26, 
p = 0.02) while MAP17 correlated with overall survival (OS) (HR 0.98, p = 0.05). 
High-MAP17 and high-pH2AX combined analysis showed improved LDS (with 61.35 
months vs 32.2 months, p = 0.05) and OS (with 66.6 months vs 39.8 months, p = 
0.01). Furthermore, the subgroup of high-pH2AX and optimal dose of cisplatin was 
also associated with OS (72 months vs 38.6 months, p = 0.03) and LDS (66.9 months 
vs 27 months, p = 0.017). These findings suggest that pH2AX alone or better in 
combination with MAP17 may become a novel and valuable prognostic biomarker for 
patients with laryngeal carcinoma treated with preservation approaches.
INtrODUctION
Squamous cell carcinoma of the head and neck 
represents 4% of all cancers diagnosed worldwide, with 
more than 500.000 new cases recorded in 2008 [1, 2]. Of 
them, 30% were laryngeal cancer with an estimated age-
standardized world mortality rate of 2.3/100.000 habitants. 
Alcohol and tobacco abuse are common etiologic factors 
[3] but exposure to hard-alloys dust, chlorinated solvents 
[4] and familiar genetic patterns [5] have been also 
implicated. The role of Human Papilomavirus (HPV) 
is well established for squamous cell carcinoma of the 
oropharynx but it remains unclear for laryngeal cancer 
[6]. Furthermore, these patients are at risk of developing 
second primary tumors due to chronic aerodigestive tract 
carcinogen exposure: 14% in 5 years, 26% in 10 years and 
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37% in 15 years [7]. The main prognostic factor for overall 
survival (OS) is tumor staging, where node invasion 
is more relevant than tumor extension [8]. Other OS 
prognostic factors are patient’s comorbidity, performance 
status-ECOG (PS) [9], persistent toxic consumption habits 
[10], second primary tumor appearance [11] and primary 
tumor localization. In particular, glottic tumors have an 
81% OS rate while supraglottic tumors drop to 70%, 
probably due to early detection [12]. Disease-free survival 
prognostic factors include PS [9, 13], node invasion [13, 
14], localization [9], pathologic stage (pT) [14], surgical 
resection margins [13] and pretreatment tracheotomy 
[15]. Moreover, T4 primary extension and more than 2 cm 
tumoral invasion of the base of the tongue were shown to 
be associated with increased salvage laryngectomy in the 
Veterans study [16].
Total laryngectomy was the gold standard treatment 
by the 1980s with subsequent loss of speech and airway 
patency [17]. Consequently, treatment aims changed in 
order to improve patient’s quality of life through larynx 
sparing approaches. Currently, early stages (I and II) 
are treated with either surgery or radiotherapy (RT) as 
they have been accepted to have similar effectiveness. 
However, both treatments have not been compared in a 
randomized trial so far. Reported five-year OS is typically 
70 to 90% [18, 19]. Advanced disease requires multimodal 
approach, usually a combination of chemotherapy (CT) 
or biotherapy (B) plus RT. Although functional organ 
sparing approaches permit larynx preservation, they do 
not provide a survival advantage over total laryngectomy 
[20]. Three sparing approaches are accepted: RT, bio or 
chemotherapy with concomitant radiotherapy (B/CT RT) 
and induction CT (ICT) followed by RT with or without 
B/CT.
CTRT with concurrent cisplatin showed higher 
preservation rates compared to other two arms with RT 
alone or induction cisplatin plus fluorouracil followed 
by RT (88% versus -vs- 70% and 75%, respectively) 
with similar two and five year survival [21]. Later, a 
10-year follow-up publication confirmed that the arms 
that included ICT improved laryngectomy-free survival 
(LFS). Contrary to preservation rates, LFS includes not 
just the need of salvage laryngectomy but also speech 
and swallowing quality. It is, therefore, more similar to 
what we currently understand as larynx preservation [22]. 
A subsequent meta-analysis for locally advanced larynx 
cancer found that adding CT concomitant with RT led to a 
benefit of 6.5% absolute improvement in 5-year OS [23].
The optimal dose of cisplatin during RT remains 
still unclear [24-26]. Two or three courses of three-
weekly cisplatin could be considered the optimal dose 
for concurrent CTRT and equivalent doses of carboplatin 
have also been accepted by expert panels. However, 
preservation approaches entail up to a 43% rate of late 
toxicities [27] and have not shown to prolong OS more 
than surgery. Interestingly, 5-year OS was reported to 
drop from 67.4% in 1985 to 61.9% in 2007 (Source: 
Surveillance, Epidemiology and End Results Program. 
Accessed: http://seer.cancer.gov/). Nevertheless, these 
results do not allow making major conclusions, as 
preservation approaches were not broadly used until the 
time of database collection.
The high rate of toxicities and the non-improved 
survival with preservation approaches lead to the 
need for biomarker development. Predictive larynx 
biomarkers would facilitate pretreatment identification 
of those patients who are unlikely going to be cured by 
radiation-based therapy. By managing these patients 
with surgery rather than a preservation approach, local 
disease control and possibly survival could potentially be 
optimized and unnecessary treatment related morbidities 
from unsuccessful larynx treatments could be avoided. 
However, there are still no clinical or molecular 
biomarkers validated in standard practice at present.
γH2AX is a component of the histone octamer in 
nucleosomes. It is phosphorylated (pH2AX) by kinases 
such as ataxia telangiectasia mutated (ATM) and ATM-
Rad3-related (ATR) upon DNA damage. PH2AX is 
involved in recruiting DNA repair proteins in response 
to the presence of DNA double-strand breaks (DSB) 
and therefore it has been studied as a biomarker of 
DNA damage for new drug development. As such, the 
presence and magnitude of pH2AX is an indication 
of persistent, unrepaired DNA damage [28]. pH2AX 
induction appears within minutes in cells after DNA 
damage and reaches maximum levels after 30 minutes. 
The repair process includes the phosphorylation of 
hundreds to thousands γH2AX surrounding the DSB site 
in order to form a focus that open the chromatin structure 
and serve as a platform for the accumulation of factors 
involved in the DNA damage response [29]. γH2AX 
phosphorylation has been studied as prognostic biomarker 
in early operable non-small cell lung cancer (NSCLC) 
and endometrial carcinomas. In the NSCLC study, low 
levels of phosphorylated γH2AX correlated with better 
survival outcomes. The combination of wild type p53 
and low-phosphorylated γH2AX phenotype showed 
also better survival. In the endometrial trial, p-γH2AX 
positively correlated with p53 levels although the relation 
with survival could not be proved. However, in both 
studies patients were treated with surgery and not with 
radiotherapy [30, 31]. 
Our goal was to determine whether pH2AX by 
itself or in combination with other molecular and clinical 
findings could be a prognosis biomarker for laryngeal 




Patients were mainly male (93.7%) with squamous 
carcinoma histopathology (100%) and good general 
condition (PS 0-1 = 96.8%). Tumors were more frequently 
localized in the supraglottic (58.7%) and 74.6% were stage 
III. Nodal involvement was observed in 25.4% of the 
patients and 6.3% had primary T4 extension. Pretreatment 
tracheotomy was required for 31.7% patients. Organ 
preservation approaches include B or CTRT (74.6%), RT 
(14.3%), or ICT-B/CTRT (9.5%) (Table 1). Most of the 
patients received concurrent CT or B during RT (82.5%). 
The preferred treatment was cisplatin 100 mg/m2 on days 
1, 22, and 43 of radiotherapy (73%) followed by weekly 
cisplatin 40 mg/ m2 (11.5%) and cetuximab (11.5%). 
Carboplatin was selected for only 4% of patients.
At the time of the analysis, 20 (32%) deaths and 29 
(46%) recurrences had occurred with a median follow-
up of 29 months (m). Locoregional relapse occurred in 
19 (30%) patients, 7 (11%) presented locoregional plus 
distant metastases, and 3 (4.8%) only distant metastases; 
of them, 14 (48.3%) were candidates for salvage surgery. 
Laryngoesophageal dysfunction (LD) occurred in 51% 
of the total; main reasons for LD were tumoral local 
recurrence (75%) followed by the need of a tracheostomy 
of feeding tube (15.6%). Mean OS was 58 m (47.7-68 m, 
CI 95%), LDS 46 m (36-55.5m, CI 95%), and LRC 54.6 m 
(44-65 m, CI 95%). Moreover, 2-year LRC rate was 63%. 
The 2-year cumulative proportion of patients with larynx 
preservation and OS were 57% and 80% respectively. 
Lymph node involvement was associated with worse OS 
(N0: 64.2m vs N1/2: 26.8 m, p < 0.01) but not with LDS 
(46.8 vs 24.6, p = 0.6) (Figure 1B and 1A). Tumor local 
extension impacted negatively on both OS and LDS (OS 
non-T4 60.7 m vs T4 22.5 m; LDS non-T4 48.5 m vs T4 
7.3m, both p = .001) (Figure 1D and 1C). Furthermore, 
patients who required pretreatment tracheotomy (PT) had 
worse OS (37.2 m vs 61.8 m, p = 0.051) and LDS (19.6 m 
vs 55.4m, p = 0.001) (Figure 1F and 1E). Therefore, our 
cohort behaves similarly to others reported in the literature 
[16, 21]. 
cisplatin and radiotherapy as prognostic markers 
in larynx cancer
As per the RTOG 0129 phase III clinical trial results, 
patient were classified by the dose of cisplatin received 
during the radiation treatment. In total, 52.4% reached 
the optimal dose of cisplatin during radiotherapy whereas 
17.5% could not reach the cisplatin optimal dose, 12.7% 
did not receive any radiosensitizer, and 14.3% were treated 
with other radiosensitizers. 3.1% were unknown. 
Cisplatin optimal dose (≥200 mg/m2) was 
associated with better outcomes for survival although 
this was statistically significant for LDS (OS: 67 m vs 39 
m, p = 0.073; LDS: 56m vs 24 m, p = 0.017; LRC: 60.4 
m vs 29 m, p = 0.12) (Figure 2B and 2A). Receiving an 
optimal dose of cisplatin showed better LDS (p = 0.023) 
than lesser doses (HR = 0.24), other radiosensitizers (HR 
= 0.32), and no concurrent radiosensitizers (HR = 0.65). 
However, this benefit was not observed for OS probably 
because the analysis did not take into account patients that 
needed salvage laryngectomy and did not preserve the 
organ. 
On the other hand, total dose of radiation delivered 
was 70 Gy as per standard local guidelines. Patients 
that completed radiotherapy within 8 or 9 weeks were 
compared to those that suffered interruptions or delays but 
no differences were found in terms of OS or LDS between 
groups (Figure 3).
pH2AX in larynx tumor samples
Out of 63 samples only 53 were analyzed for 
pH2AX expression either due to technical problems 
or because they did not contain any tumor cellularity. 
Positive pH2AX expression, considered as any 
percentage of tumoral nuclei with positive staining, 
was shown in 46 (86.8%) samples with a range of 1 to 
70 and median expression of 10 (Figure 4A). In order to 
distinguish a cutoff point for pH2AX levels a ROC curve 
was performed and punctuation of 5.25 score chosen 
(supplementary Figure 1). Levels of pH2AX were equally 
distributed among tumor grades (Figure 4B) suggesting 
independence from this clinical feature, as the Chi-square 
test showed no differences between groups (p = 0.8). 
When measured as a continuous variable, pH2AX 
had a significant positive influence with better LDS 
outcomes (HR 0.95, p = 0.02), although this was not 
significant for OS. As a dichotomous variable, a trend 
towards better OS, LDS and LRC was observed but 
just LDS was statistically significant in the multivariate 
analysis (HR 0.26, p = 0.02) (Table 2) (Figure 3C, 3D and 
3E).
pH2AX and clinical findings
We also studied the potential correlation between 
pH2AX and clinical findings such as tumor localization, 
tumoral stage, smoking habit, alcohol consumption and 
acute toxicity development with no statistically significant 
association. These results suggest pH2AX to be an 
independent prognostic factor, as it remains significant 
after controlling for these variables. 
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pH2AX relationship with cisplatin and 
radiotherapy
The total dose of cisplatin was not associated with 
pH2AX levels (p = 0.4). We created a variable with two 
categories from pH2AX and cisplatin, in which one had 
a potential favorable prognosis (high-pH2AX levels, 
and optimal dose of cisplatin, ≥200 mg/m2), and the 
other unfavorable prognosis (low-pH2AX levels, and/
or suboptimal dose of cisplatin < 200mg/m2 or other 
radiosensitizers due to the low number of patients). The 
favorable prognosis group correlated with increased OS, 
LDS (OS: 72 m vs 38.6 m, p = 0.03; LDS 66.9 m vs 27 m, 
p = 0.019). LRC was not statistically significant (p = 0.17) 
although there was a trend towards better outcomes in the 
good prognostic subgroup (69.9 m vs 35.1 m) (Figure 5A, 
5B and 5C). Moreover, the unfavorable prognosis group 
correlated with worse OS (HR = 3.66, p = 0.044), and 
LDS (HR = 3.38, p = 0.028). LRC has a not statistically 
significant HR (HR = 2.4, p = 0.188).
We also tried to stablish whether high-pH2AX and 
no radiotherapy delays could impact on survival but no 
differences were found for both OS and LDS. 
correlation of pH2AX with p53 and KI67
We also analyzed other markers for proliferation 
such as KI67 or the activated form of ERK (phosphorylated 
ERK, ERK-p), and apoptosis such as mutant (m) p53 or 
activated AKT (phosphorylated AKT, AKT-p). Our cohort 
showed a percentage of positive samples for ERK-p or 
AKT-p, but these groups did not show correlation with 
pH2AX expression (data not shown). KI67 in combination 
with pH2AX was not significant in any combination 
(data not shown), being pH2AX also independent of the 
proliferative capability of the tumor. Our results showed 
no correlation between p53 and pH2AX although there 
was a relation towards increased pH2AX with negative 
P53 ( < 5% positive nuclei) that was not statistically 
significant (p = 0.33).
However, in our cohort p53 samples positive 
(measured as >5% positive nuclei) (Figure 6A, + p53) 
correlated with worse OS (- p53 = 50 vs + p53 = 35.6 m, 
p = 0.047) (Figure 6B) consistent with previous literature 
[34].
P53 and pH2AX were combined into a new 
variable with the following categories: potential good 
table 1: Population characteristics and treatment
Population characteristics No.             %
Mean age                                                     63.7 years
Male 59 93.7
squamous cell carcinoma 63 100.0
Smokers of ≥ 10 pack-years 59 93.7
regular alcohol intake 45 71.4
PS 0-1 61 96.8
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PS: Performance status-ECOG; B/CTRT: bio/chemoradiotherapy; ICT-B/
CTRT: induction chemotherapy followed by bio/chemoradiotherapy.
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Figure 1: A. and b. N0 compared with N positive LDS/OS. OS was better in the patients who had no lymph node involvement. c. and 
D. T4 local tumor extension shows worse OS and LDS than the rest of patients. E. and F. worse LDS and OS is observed in patients who 
required pretreatment tracheotomy (PT). 
Figure 2: A. and b. Cisplatin (Cpt) optimal dose (≥200 mg/m2) showed significant LDS benefit that was not maintained for OS. 
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prognosis phenotype (negative p53 and high-pH2AX) and 
unfavorable prognosis phenotype (positive p53 and low-
pH2AX). Although there was an apparent relation towards 
better outcomes in the good prognosis phenotype, this was 
not significant for both OS and LDS (OS: 48.6 m vs 39 m, 
p = 0.39; LDS: 38.8 m vs 24.4 m, p = 0.068) (Figure 6C 
and 6D).
correlation of pH2AX and MAP17
We have recently shown that MAP17, 
a small non-glycosylated membrane protein 
overexpressed in carcinomas, expression analyzed 
by immunohistochemistry is associated with OS (p < 
0.001) and LDS (p = 0.002) [32]. MAP17 increases 
endogenous ROS [35, 36]. Since ROS is a well-known 
mediator of DNA damage [37], we measured whether 
pH2AX correlated with MAP17 expression and whether 
the combination of both markers could strength the 
predictability of responses. 
We found that patients with high levels of MAP17 
and subject to optimal doses of cisplatin had better LDS 
(58.6 m vs 32.6 m, p = 0.053) and OS (76.2 m vs 40.9 
m, p = 0.005) than patients with low MAP17 or not 
subject to optimal doses of cisplatin (Figure 7A and 7B). 
Furthermore, patients with high levels of MAP17 and 
high-pH2AX, denoting higher structural DNA-damage, 
conform the group of better prognosis after therapy 
(Figure 7C and 7D).
Moreover, patients with high-MAP17, high-pH2AX 
and optimal dose of cisplatin had better OS and LDS than 
the rest of the population (Figure 7E and 7F), and when 
compared with poor prognosis phenotype (low-MAP17, 
low-pH2AX and suboptimal cisplatin dose) (Figure 7G 
and 7H).
DIscUssION
In this manuscript, we have shown that pH2AX has 
a prognostic role in patients with laryngeal cancer. We 
hypothesize, taking into account the combined analysis 
with p53 and MAP17, that the DDR pathway could have 
an essential role in laryngeal cancer. Although further 
research is needed, we think that our results are opening 
a new window to identify biomarkers that in the future 
may allow changes in clinical practice, as to date there 
are no biomarkers that could identify those patients that 
will benefit from radiotherapy-based treatments instead of 
surgery.
We found that pH2AX was related to LDS (High-
pH2AX HR 0.26, p = 0.02) in a cohort of 53 patients with 
larynx cancer. When analyzed together pH2AX expression 
and dose of cisplatin received during radical treatment, 
there is a significant correlation with survival (high-
pH2AX and optimal dose of cisplatin 72 months vs 38.6 
months, p = 0.03) and LDS (high-pH2AX and optimal 
dose of cisplatin 66.9 months vs 27 months, p = 0.019). 
Our data suggest that inherent DDR pathway activation 
(measured by the end-point of phosphorylation of H2AX) 
is a valuable prognostic marker in patients with laryngeal 
carcinoma who received preservation approaches. Our 
data also show the importance of performing optimal 
table 2: LDs and Os multivariate analysis 
LDs Os
Hr p-value cI Hr p-value cI
Pt 1.41 0.59 0.39-5.08 Pt 0.96 0.98 0.17-5.58
Non-primary T4 









High-pH2AX 0.26 0.02 0.09-0.78 High-pH2AX 0.57 0.46 0.13-2.55
KI 67 1.03 0.15 0.99-1.06 KI 67 1.06 0.038 1.00-1.12
MAP17 1.01 0.63 0.99-1.02 MAP17 0.98 0.05 0.95-1.00
P53 0.99 0.37 0.56-1.02 P53 1.03 0.12 0.99-1.07
pErK 0.99 0.35 0.97-1.01 pErK 1.01 0.65 0.98-1.04
pAKtP 0.99 0.41 0.98-1.01 pAKt 0.98 0.16 0.96-1.01
LDS: laryngoesophageal dysfunction-free survival. OS: overall survival. HR: hazard ratio. CI: confidence interval. PT: 
pretreatment tracheotomy. N: pathological lymph nodes.
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cisplatin treatment for tumor response. However, the fact 
that unexpected radiotherapy delays and interruptions did 
not affect survival in our cohort could be explained to 
dose compensations. Radiobiological-based calculations 
were performed in those patients in order to achieve an 
equivalent biological effectiveness by adding some more 
fractions to the overall treatment. 
Tumor cells from clinical specimens show 
constitutive activation of DNA damage signalling as 
demonstrated by the presence of gH2AX phosphorylation 
and other DDR signalling proteins [38-40]. This DDR 
activation was found to peak at early stage tumors, 
persisting further among malignant tumors mostly by 
inactivating p53 gatekeeper [40]. It has been proposed 
that the DDR-network may serve as an inducible barrier to 
control the initial steps of tumor development by inducing 
p53-dependent senescence or apoptosis [38-40]. Further 
ongoing chronic DDR activation favours the outgrowth 
of malignant clones with genetic or epigenetic defects 
in DNA-repair mechanism such as those involved in the 
DDR pathway [40]. Our samples, from already malignant 
tumors (stages II-IV), in which only a subset of them 
Figure 3: A. and b. No differences were found for radiotherapy delivered within less than 9 weeks or ≥9 weeks in terms of LDS or OS. 
C and D. Same results for a cut-off of 10 weeks.
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showed mutant p53, correlated with worse onset of the 
disease. It is likely DNA-damage defects inducing DDR 
activation have been carried through the malignant process 
and it is possible that other proteins are mutated in the 
process avoiding the requirement for p53 inactivation.
pH2AH is a broad DNA damage marker that appears 
under different physiological conditions. Senescent cells 
display molecular characteristics of DNA damage [41-
43]. These markers include nuclear foci of phosphorylated 
histone H2AX, the localization at double-strand break 
sites of DNA-repair and DNA-damage checkpoint factors, 
such as 53BP1, MDC1 and NBS1 [44-46]. Senescent 
cells also contain activated forms of the DNA-damage 
checkpoint kinases Chk1 and Chk2. During replicative 
senescence, markers of a DNA damage response localize 
at telomeres [45, 47], indicating that the DNA damage 
response is triggered by telomere shortening [48]. 
Similarly, the redox potential also results in DNA damage 
and senescence [49]. Very interestingly, oncogene-induced 
senescence has been found to induce DNA-damage due 
to an excess of replication forks. This oncogenic-induced 
hyper-replication signal, or replication stress, is associated 
with persistent DNA-damage [50, 51] inducing senescence 
[52]. Therefore, not only senescence is viewed as a 
response to DNA-damage, but DNA-damage as a marker 
of senescence. In that sense, high pH2AX appeared in 
early stage tumors and is a marker of good prognosis 
[38, 53, 54]. However, in our cohort, pH2AX levels are 
increased in advanced stages of tumors, and contrarily to 
this hypothesis, are a marker of bad prognosis, indicating 
that our pH2AX observations are not due to cellular 
senescence, neither by continuous proliferation nor by 
replication stress. 
In that line, phosphorylation of H2AX is not 
always a marker of DNA damage. It also can be a marker 
of activated mTOR, eliciting replicative stress and a 
Figure 4: A. Positive pH2AX expression, considered as nuclei staining was shown in 46 (86.8%) samples. b. Levels of pH2AX are 
equally distributed among tumor stages. c., D. and E. high-pH2AX show a trend towards better OS, LDS and LRC not statistically 
significant in the Kaplan-Meier analysis. 5.25 as indicated by the ROC curve were used as cut-off for defining high and low expression of 
pH2AX for survival analysis.
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Figure 5: A., b. and c. pH2AX and dose of concomitant cisplatin were combined in a new variable where high-pH2AX and cisplatin 
(Cpt) ≥200 mg/m2 was considered as good prognosis phenotype category. The results show improved OS and LDS in this subgroup, and 
a trend towards better LRC. 5.25 as indicated by the ROC curve were used as cut-off for defining high and low expression of pH2AX for 
survival analysis.
Figure 6: A. P53 was measured as >5% positive nuclei, as shown in the picture. b. positive P53 (+ P53) correlates with worse OS in our 
cohort. c. and D. results of the combination of P53 and pH2AX in a new variable. Although there was a trend towards better outcomes in 
the good prognosis phenotype which included negative P53 (-P53) and high-pH2AX, this was not statistically significant for OS and LDS.
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pseudo DNA-damage in senescent cells [46, 51, 55-58]. 
The dynamics of senescence exhibit 2 different steps: 
cell cycle arrest and further acquisition of senescence 
features, which includes permanent arrest, termed 
geroconversion [51, 58-60]. If geroconversion is not 
activated, cells are only transiently arrested with the 
possibility of resuming growth once the proliferation 
constraints have been eliminated [44, 61]. It has also 
been shown that if mTOR is activated under conditions 
of proliferative arrest, then arrest becomes permanent and 
the cell undergoes senescence [59, 60, 62]. Under these 
conditions of cell cycle arrest and mTOR activation, 
the phosphorylation of H2AX is launched, becoming a 
marker of cellular senescence [46, 52, 55, 62]. In fact, 
rapamycin treatment, which inhibits mTOR, can divert 
senescence into quiescence, allowing the cell to resume 
growth once conditions are more favorable [63-66]. Since 
mTOR is the master regulator of protein synthesis [67], 
it has been proposed that this contribution is due to the 
function of mTOR as a sensor of cellular nutrients and 
energy status as well as growth factor signals [68, 69]. 
However, it has also been reported that mTOR activation 
in the context of growth arrest is perceived by the cells as 
and unwanted oncogenic signal, activating the replicative 
stress and pseudo DNA-damage signaling [46, 52, 55, 62]. 
In any case, high levels of pH2AX as marker of cellular 
senescence should be associated to better prognosis, and 
to some extent to early stage tumors. However, it will be 
of interest to correlate the levels of pH2AH with those of 
mTOR activation in laryngeal tumors to provide a more 
accurate hypothesis of the pH2AH inducers.
Our data show that high levels of pH2AX correlate 
with better prognosis after treatment with DNA-damage 
agents such as cisplatin and radiotherapy, especially 
if cisplatin is given at optimal doses. These data are 
suggestive of a collaboration of DDR pathway activation, 
perhaps as an indicator of low DNA-repair ability and 
DNA-damaging agents in tumor therapy. The fact that 
doses of cisplatin are important for survival (Figure 2) 
seems to confirm this hypothesis. In line with this, wt-
P53 with high levels of pH2AX conforms a subgroup of 
good prognosis (Figure 6) suggesting that P53 activity is 
essential to drive physiological response to apoptosis (or 
senescence) of DNA-damage agents in tumors with DDR 
activated.
These data are opposite to the found in early 
operable non-small cell lung cancer (NSCLC). In this 
study, low levels of pH2AX correlated with better 
survival outcomes. The combination of wild type p53 
and low-phosphorylated γH2AX phenotype showed also 
better survival. However, NSCLC patients were treated 
with surgery and not with radiotherapy [30]. This lack 
of treatment with radiotherapy could be the cause of the 
different behavior respect the pH2AX. Radiotherapy 
increases oxidative stress and reactive oxygen species 
that in combination with preexisting DNA damage can 
increase cell damage above threshold inducing increased 
tumor efficacy. Our data support this hypothesis since 
combination with another ROS-inducing agent such 
as cisplatin is essential to gain better survival in these 
patients. Furthermore, the combination of MAP17, a 
known ROS-inducing oncogene [32, 35, 36, 70] also 
supports the essential role of radiotherapy in this response. 
We have recently shown that MAP17 levels, a 
small non-glycosylated membrane protein overexpressed 
in carcinomas, are associated with overall survival (p < 
0.001) and laryngoesophageal dysfunction-free survival (p 
= 0.002) [32]. MAP17 increases endogenous ROS [35, 36, 
70]. ROS are well known mediators of DNA damage [37]. 
Our data suggest that high levels of MAP17 induced ROS 
that in turn increases DNA-damage and DDR signaling. 
Upon further DNA-damage and further increase in ROS 
molecules induced by cisplatin and RT treatment, tumors 
with higher oxidative stress (higher MAP17, higher ROS 
denoted by higher pH2AX), are more suitable to undergo 
apoptosis in the presence of P53 activity. Therefore, 
our data seems to confirm that pH2AX is a marker of 
structural DNA-damage in the laryngeal tumors that may 
become a novel and valuable prognostic biomarker for 
laryngeal carcinoma.
MAtErIALs AND MEtHODs
Patient’s characteristics and treatment
We evaluated 63 patients with larynx cancer from 
August 2005 to February 2014. However, out of the 63 
tumoral samples, only 53 of them could be studied. All 
samples were obtained from diagnostic biopsies before 
any treatment. All patients completed the informed consent 
form and the project was approved by the local ethical 
committee at the HUVR (PI13/059). Patients received 
treatment in our institution but tumor samples were 
obtained from four different national hospitals where the 
diagnosis was made. Eligibility criteria for preservation 
include patients with stage II-IV laryngeal tumors that had 
no contraindication for chemotherapy and/or radiotherapy, 
significant cartilage destruction, or more than 2 cm 
tumoral invasion of the base of the tongue. TNM Staging 
System for the Larynx (7th ed., 2010) was used for tumor 
classification. This cohort has been previously reported in 
[32]. 
tissue acquirement and preparation
Formalin-fixed, paraffin-embedded tissue sections 
from 63 laryngeal carcinomas were selected with the 
collaboration of the Andalusian Health Care Biological 
Resource Centre. Histological characterization of all 
samples was done by Hematoxylin and Eosin staining, 
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Figure 7: A. and b. the combination of high-MAP17 and optimal doses of cisplatin (Cpt) showed better OS and LDS. c. and D. patients 
with high-MAP17 and high-pH2AX with higher structural DNA-damage showed to have better OS and LDS. E. and F. survival for 
patients with high-pH2AX, high-MAP17 and optimal dose of cisplatin was statistically better. G. and H. the subgroup of patients with 
high-pH2AX, high-MAP17 and cisplatin optimal dose patients was compared to the patients that had low-pH2AX, low-MAP17 and did 
not complete cisplatin. Although limited in numbers, none of the patients with poor prognosis phenotype reached more than 2-years LDS 
or more than 3-years OS.
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followed by immunohistochemistry (IHQ) analysis of 
tissue microarrays (TMA).
Immunohistochemistry
Three-micrometer slices were sectioned from the 
TMA block and applied to coated, immunochemistry 
slides (DAKO, Glostrup, Denmark). The slides were 
baked overnight in a 56°C oven, deparaffinized in xylene 
for 20 min, rehydrated through a graded ethanol series and 
washed with PBS. A heat-induced epitope retrieval step 
was performed by heating a slide in a solution of sodium 
citrate buffer pH 6.5 for 2 min in a conventional pressure 
cooker. After heating, the slides were incubated with 
proteinase K for 10 min and rinsed in cool running water 
for 5 min. Endogenous peroxide activity was quenched 
with 1.5% hydrogen peroxide (DAKO) in methanol for 
10 minutes, and incubation with the primary antibodies 
anti-gamma H2A.X (phospho S139) antibody (ab11174 
from Abcam) and anti-p53: p53 FL 393 (sc-6243 from 
Santa Cruz); was performed for 40 min. After incubation, 
immunodetection was performed with the EnVision 
(DAKO, Glostrup, Denmark) visualization system using 
diaminobenzidinechromogen as the substrate, according 
to the manufacturer’s instructions. Immunostaining was 
performed in a TechMate 500 automatic immunostaining 
device (DAKO) and measured through a double-
blind visual assessment using microscopic observation 
according to the anatomopathological experience 
of pathologists. Sample scoring was performed by 
microscopic analysis, considering the percentage of nuclei 
stained cells.
Statistical analysis and definitions
Kaplan-Meier method was used for survival 
analysis, using Cox Proportional Hazards model to adjust 
for the explanatory variables, obtain the p-values and 
estimate the hazard ratios (HR). Multivariate logistic 
regression was used to obtain odds ratio (OR) and 
confidence intervals (CI 95%). Pearson’s correlation 
measured dependence between quantitative variables. 
A receiver operating characteristic (ROC) curve was 
performed to assess pH2AX cutoff point (two-year OS), 
which we checked using the optimal Youden index-based 
point. In addition, a log-rank test compared the survival 
distributions between high and low PH2AX both as a 
single variable and in combination with cisplatin optimal 
dose, MAP17 and p53. Categorical data were studied with 
contingency tables that included Chi-square statistics. 
Calculations were performed using SPSS 15.0 software.
OS has been defined as the length of time from 
diagnosis until the last medical record. LCR was measured 
as length of time from diagnosis until the relapse or last 
medical record, in those patients who did not develop 
distant metastases or died due to different causes than 
the tumor. For laryngoesophageal dysfunction-free 
survival (LDS) we adopted Lefebvre Larynx Preservation 
Consensus Panel that included as endpoint events: death, 
local relapse, total or partial laryngectomy, tracheotomy at 
two or more years, or the presence of a feeding tube at two 
or more years [33].
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